Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Mar;5(3):301-14.
doi: 10.4155/fmc.12.206.

Microvascular complications and diabetic retinopathy: recent advances and future implications

Megha Barot  1 , Mitan R Gokulgandhi, Sulabh Patel, Ashim K Mitra
Affiliations
Review

Microvascular complications and diabetic retinopathy: recent advances and future implications

Megha Barot et al. Future Med Chem. 2013 Mar.

Abstract

Retinal microvascular alterations have been observed during diabetic retinopathy (DR) due to the retinal susceptibility towards subtle pathological alterations. Therefore, retinal microvascular pathology is essential to understand the nature of retinal degenerations during DR. In this review, the role of retinal microvasculature complications during progression of DR, along with recent efforts to normalize such alterations for better therapeutic outcome, will be underlined. In addition, current therapeutics and future directions for advancement of standard treatment for DR patients will be discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Microvascular and mitochondrial dysfunctions in diabetic retinopathy.
Figure 2
Figure 2
Cis-combretastatin A4.
Figure 3
Figure 3
C9 or 2H-indol-2-one, 1, 3-dihydro-6-methoxy-1-methyl-3-[(3,4, 5-trimethoxyphenyl) methylene]-, (3E)- (9CI).
Figure 4
Figure 4
PKC412 (midostaurin).
Figure 5
Figure 5
MnTBAP.
Figure 6
Figure 6
M40403 (imisopasem manganese).
Figure 7
Figure 7
PJ-34.
Figure 8
Figure 8
FP-15.
See this image and copyright information in PMC

References

    1. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye (Lond) 2009;23(7):1496–1508. - PubMed
    1. Gardner TW, Antonetti DA, Barber AJ, Lanoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47(Suppl 2):S253–S262. - PubMed
    1. Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M. Effect of ruboxistaurin on blood–retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest Ophthalmol Vis Sci. 2005;46(10):3855–3858. - PubMed
    1. Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr Diab Rep. 2011;11(4):253–264. Provides insight into novel technologies and innovative cellular targets that may give hope for developing ‘next-generation’ interventional or preventive clinical approaches that will significantly advance current standards of care and clinical outcomes for the treatment of diabetic retinopathy. - PubMed
    1. Wong TY, Klein R, Sharrett AR, et al. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA. 2002;287(19):2528–2533. - PubMed

Websites

    1. Diabetic retinopathy: future demand to be driven by agents that improve visual acuity. http://decisionresources.com/Products-andServices/Report.Aspx?R=Dbaspd1408.
    1. Hoffmann-La Roche Ltd. www.roche.com/Investors/Ir_Update/Inv-Update-2011-2006-29.Htm.
    1. Study evaluating the safety and response of fosbretabulin in asian patients with polypoidal choroidal vasculopathy (PCV) http://clinicaltrials.gov/ct2/show/NCT01023295.
    1. Safety and efficacy study of combretastatin A4 phosphate to treat patients with choroidal neovascularization secondary to pathologic myopia. http://clinicaltrials.gov/ct2/show/NCT01423149.
    1. A safety and efficacy study of E10030 (anti-PDGF pegylated aptamer) plus lucentis for neovascular age-related macular degeneration. http://clinicaltrials.gov/ct2/show/NCT01089517.

Publication types

MeSH terms